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Previewscell-cell communication to increase our
fundamental understanding of how pre-
malignant cells utilize the microenviron-
ment to promote their malignant agenda.
These insightswill ultimately result in novel
therapeutic strategies, targeting niche
cells to attenuate leukemic progression.REFERENCES
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The development of curative therapies for genetically complex diseases such as ALS has been delayed by
the lack of relevant disease models. Recent advances using induced-pluripotent-stem-cell-derived moto-
neurons from patients harboring distinct ALS mutations have recapitulated essential disease features and
have identified some common pathways driving disease pathogenesis.Amyotrophic lateral sclerosis (ALS) is a
progressive neurodegenerative disorder
involving the loss of motoneurons in the
spinal cord and motor cortex, leading to
paralysis and premature death. Whereas
most ALS cases are sporadic (sALS),
around 10% are considered familial and
mainly inherited in a dominant manner
(fALS), involving mutations in more than
two dozen genes, including superoxide
dismutase 1 (SOD1), Tar DNA-binding
protein-43 (TDP-43), fused-in-sarcoma
(FUS), and C9orf72. The biology of ALS is
very complex; however, it is known that
thepathology is specific tomotor neurons.
Multiple pathogenic mechanisms have
been proposed to contribute to the selec-
tive motoneuron degeneration, including
alterations in RNA metabolism, mitochon-
drial dysfunction, abnormal protein aggre-
gation, endoplasmic reticulum (ER) stress,excitotoxicity, axonal transport defects,
and gliosis, among other events.
Most cellular and animal models of
ALS involve the expression of supraphy-
siological levels of human transgenes,
mostly involving mutant SOD1 and
TDP-43, which contrasts with the single
allele alteration observed in fALS cases.
Although these ALS models have been
fundamental to investigate disease path-
ogenesis, drugs identified to abrogate
or delay experimental ALS using these
models have failed in clinical trials. These
shortcomings underscore the need for
novel model systems to assess unique
events that may underlie the selective
neuronal vulnerability observed in human
cells. Induced pluripotent stem cells
(iPSCs) generated from ALS patients and
differentiated into motoneurons represent
a promising new tool for studying ALSdisease pathology. Using stem cell ap-
proaches, three recent studies reported
in Cell Stem Cell (Kiskinis et al., 2014;
Chen et al., 2014) and Cell Reports
(Wainger et al., 2014) revealed the occur-
rence of inherited abnormal cellular
phenotypes in ALS patient-derived
motoneurons involving distinct genetic
mutations. Remarkably, common path-
ways of degeneration have emerged
through these studies (Figure 1), opening
the possibility of new and effective drug
screening.
Kiskinis et al. (2014) and Chen et al.
(2014) both established new in vitro
models of ALS by generating iPSC-
derived motoneurons from patients car-
rying SOD1 mutations. Both studies
developed a well-controlled cellular sys-
tem by combining genetic correction of
the SOD1 mutation and whole-genomell 14, June 5, 2014 ª2014 Elsevier Inc. 697
Figure 1. Discovery of Common Molecular Mechanisms of ALS Pathogenesis using iPSC-Derived Human Motoneurons
Recent studies using human motoneuron cultures from ALS patients with distinct genetic mutations have identified transversal pathological mechanisms, facil-
itating the development of experimental strategies to revert distinct disease features, including abnormal protein and RNA aggregation, hyperexcitability,
morphological alterations, and cell death.
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Previewssequencing to ensure the isogenic back-
grounds of their samples. The authors
generated highly enriched and electro-
physiologically active motoneuron cul-
tures and recapitulated the spontaneous
and progressive decrease in cell viability
observed in humans, verifying that the
phenotype was dependent on the ex-
pression of mutant SOD1 (Kiskinis et al.,
2014, Chen et al., 2014). ALS-related
morphological changes were recapitu-
lated in vitro, including the reduction in
soma size and altered dendrites, which
was linked to the deregulation and aggre-
gation of neurofilaments, an event that
preceded the occurrence of neuronal
apoptosis (Chen et al., 2014). Although
mutant SOD1 aggregation is thought to
be a key molecular event driving neuro-
toxicity, in these two studies the levels
of mutant SOD1 aggregation were
extremely low and only detected after in-
hibiting the proteasome or by extremely
sensitive methods (e.g., immunogold
staining followed by electron microscopy
analysis), consistent with the idea that
soluble oligomeric forms of mutant
SOD1 are the pathogenic species.
Membrane hyperexcitability is a char-
acteristic and predictive feature of ALS.
Wainger et al. (2014) demonstrated that
iPSC-derived motoneurons from patients
carrying SOD1, C9orf72, or FUS muta-
tions all reproduce the spontaneous
hyperexcitability observed in disease in
culture, making them a useful tool for698 Cell Stem Cell 14, June 5, 2014 ª2014 Efuture in vitro drug screenings. Impor-
tantly, pharmacological testing revealed
that the clinically approved anticonvul-
sant drug retigabine reversed the patho-
genic phenotype and improved the
survival of human motoneurons express-
ing mutant SOD1. In an effort to define
global perturbations in cell homeostasis,
Kiskinis et al. (2014) measured the
changes in gene expression triggered in
mutant SOD1-expressing motoneurons.
Several gene clusters were misregulated
in fALS neurons, involving proteins
related to cytoskeleton, mitochondrial,
and proteostasis control. The latter ob-
servation, and a vast body of functional
studies in ALS (Hetz and Mollereau,
2014), led the authors to explore the
contribution of ER stress and the
unfolded protein response (UPR) to
mutant SOD1 pathogenesis, demon-
strating a positive impact on neuronal
survival and morphogenesis (Kiskinis
et al., 2014). Using pharmacological
approaches to modulate ion channels, a
functional link between the electrical
activity of motoneurons and the occur-
rence of basal ER stress was pro-
vided. In addition, targeting the UPR
altered the conductivity of motoneurons,
suggesting feedforward mechanisms.
Finally, the authors confirmed that a sub-
set of these transcriptional responses is
conserved in motoneurons expressing
a C9orf72 mutation, the most common
genetic alteration in ALS, thus increasinglsevier Inc.the overall implications of these findings
for a variety of ALS genetic subtypes.
Recent studies have attempted to
develop a model of sALS using iPSCs.
Remarkably, iPSCs derived from sALS
patients presented de novo TDP-43
intranuclear inclusions on a subgroup
of clones (Burkhardt et al., 2013), which
represents the most common histopatho-
logical hallmark of ALS. The authors
used this abnormal parameter to screen
a library of FDA-approved compounds.
Similarly, a drug screeningwas performed
to identify small molecules that improve
survival of motoneurons expressing
mutant SOD1 (Yang et al., 2013). Other
studies obtained conflicting results when
motoneurons were generated with iPSCs
from ALS patients carrying TDP-43 muta-
tions. In one report, ALS motoneurons
underwent cell death, correlating with
the accumulation of TDP-43 aggregates
(Bilican et al., 2012), whereas another
group did not detect any spontaneous
apoptosis, but observed dendrite alter-
ations and enhanced vulnerability to
oxidative stress (Egawa et al., 2012).
Similarly, two recent studies showed the
presence of abnormal RNA foci and the
accumulation of non-ATG-dependent
translation peptides in iPSC-derived
motoneurons from patients carrying
C9orf72 mutations (Donnelly et al., 2013;
Sareen et al., 2013). These cells were
more susceptible to glutamate toxicity
and presented global alterations in RNA
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Previewsmetabolism, which was reverted by anti-
sense oligonucleotides to target C9orf72
mRNA. Taken together, these studies
reveal that iPSC-derived motoneurons
from ALS patients develop common path-
ological features resembling early stages
of the disease that could be used to test
novel therapeutic strategies, and they
support the occurrence of an intrinsic
vulnerability to stress. They also caution
that the appearance of morphological
changes does not always culminate in
motoneuron loss. These reports addition-
ally suggest a substantial prevalence of
gain-of-toxic and cell-autonomous mech-
anisms of neurodegeneration in ALS.
The current studies illustrate that the
use of combinatorial approaches to
study iPSC-derived motoneurons offers
a well-controlled cell culture model of
ALS. The identification of robust and
inherited morphological, biochemical,
and electrophysiological phenotypes in
iPSC-derived neurons supports and
sometimes contrasts with the well-estab-
lished animal models of the disease and
will open the possibility of developingnovel drug screenings with therapeutic
potential and the identification of novel
biomarkers of ALS. These advances will
also facilitate the future generation of
personalizedmedicine through the testing
of drugs to alleviate selective pathological
events that may be unique to the specific
genetic landscape of each patient, open-
ing important avenues for the treatment
of this fatal disease.ACKNOWLEDGMENTS
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In this issue, Chung et al. (2014) generate human embryonic stem cells by fusing an adult somatic cell to a
previously enucleated human oocyte, in agreement with recent reports by the Mitalipov and Egli groups.
We can now safely say that human somatic cell nuclear transfer is alive and well.Last year, the group led by Shoukhrat
Mitalipov published, for the first time,
their success in generating hESCs using
cloned human embryos (Tachibana et al.,
2013). The field of SCNT, launched by
Dolly in 1997, has since been developed
by the successful cloning of more than
twenty different mammalian species.
Using hSCNT to generate hESCs, how-
ever, turned out to be more challenging
(Cibelli et al., 2001; Fan et al., 2011; French
et al., 2008; Noggle et al., 2011; Stojkovicet al., 2005). Mitalipov’s group spent a
significant amount of time refining SCNT,
first with monkeys and then with humans.
As a result, we now know how to over-
come some fundamental roadblocks.
The study by Chung et al. (2014), pub-
lished in this issue along with a recently
published paper by Yamada et al. (2014),
brings to light fundamental aspects of
hSCNT, reasserting this technique as a
powerful research and therapeutic tool
(Chung et al., 2014; Yamada et al., 2014).Prior to the publication of this work
and based on studies comparing donor
nuclei from ESCs with those of somatic
cells, there was a general notion that
less differentiated cells would serve as
better sources of donor nuclei. Chung
et al.(2104) successfully dedifferentiated
somatic cells from a 75-year-old donor,
which is a landmark achievement that
refutes the hypothesis that cells from an
older individual are harder to dedifferen-
tiate. Borrowing from half a century’sll 14, June 5, 2014 ª2014 Elsevier Inc. 699
